Abstract:e12040 Background: Chemotherapy followed by endocrine therapy is the standard adjuvant treatment strategy for estrogen receptor-positive breast cancer patients. However, no direct evidence so far demonstrated better efficacy of sequential use of chemotherapy and endocrine therapy over concurrent. Objective: To evaluate the efficacy between sequential and concurrent use of chemotherapy and endocrine therapy in the adjuvant treatment of ER positive breast cancer. Methods: Randomized clinical trials comparing chemotherapy and/or endocrine therapy in the adjuvant treatment of ER positive breast cancer were included. Hazard ratios (HRs) of disease-free survival (DFS) and overall survival (OS) were extracted and analyzed in Bayesian analysis. Patients were stratified by menopause status for subgroup analysis. Results: 37 trials were identified with 37225 patients enrolled in total, 37 trials with DFS results and 24 with OS. 3 comparisons were done between sequential and concurrent arms. In DFS analysis, no statistical significance was found in all 3 comparisons [CHE seq/con TAM (HR 1.01, 95%CI 0.8497 - 1.199); CHE seq/con OFS+TAM (HR 0.9119, 95%CI 0.5666 - 1.49); CHE seq/con OFS+AI (HR 1.032, 95%CI 0.6291 - 1.776)]. The same were seen in OS analysis [CHE seq/con TAM (HR 0.9512, 95%CI 0.8053 - 1.125); CHE seq/con OFS+TAM (HR 1.065, 95%CI 0.6344 - 1.789); CHE seq/con OFS+AI (HR 1.069, 95%CI 0.665 - 1.717)]. Rankings were done for preferable treatment recommendations. In DFS analyses, sequential arms ranked higher than concurrent arms [CHE seq/con OFS+AI (1 vs. 3); CHE seq/con OFS+TAM (6 vs. 7); CHE seq/con TAM (8 vs. 8)]. The same tendency was seen in OS analyses [CHE seq/con OFS+AI (1 vs. 2); CHE seq/con TAM (4 vs. 5)] except for CHE seq/con OFS+TAM (11 vs. 6-9). In subgroup ranking results, CHE seq/con OFS+AI and CHE seq/con OFS+TAM showed consistency among comparisons with concurrent arms ranked higher than sequential arms. However, CHE seq TAM ranked higher than CHE con TAM in all comparisons. Conclusions: The combination of chemotherapy and endocrine therapy in the adjuvant treatment of ER positive breast cancer demonstrated equal efficacy either used sequentially or concurrently. However, concurrent arms were recommended over sequential arms in premenopausal patients for better DFS and OS, except for the combination of chemotherapy and tamoxifen which was recommended to be used sequentially. Others: This study has been registered in PROSPERO (CRD42018104889).

Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis

Efficacy and Safety of Initial Five Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis.

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis

Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis

Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis

Sequential Versus Concurrent Adjuvant Chemo-Endocrine Therapy for HR+ Early Breast Cancer: a Systematic Review and Bayesian Network Meta-Analysis.

Sequential Versus Concurrent Use of Chemotherapy and Endocrine Therapy in the Adjuvant Treatment of ER-positive Breast Cancer: A Systematic Review and Bayesian Network Meta-Analysis.

Efficacy And Tolerability Of Toremifene And Tamoxifen Therapy In Premenopausal Patients With Operable Breast Cancer: A Retrospective Analysis

A Comparison of Survival Outcomes and Side Effects of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients: a Retrospective Cohort Study

Effect of First-Line Endocrine Therapy in Patients with Hormone-Sensitive Advanced Breast Cancer: a Network Meta-Analysis

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

Endocrine Therapy As Adjuvant or Neoadjuvant Therapy for Breast Cancer: Selecting the Best Agents, the Timing and Duration of Treatment

Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen

Adjuvant Ovarian Suppression for Premenopausal Hormone Receptor-Positive Breast Cancer

Five or More Years of Adjuvant Endocrine Therapy in Early Breast Cancer:A Meta-analysis

The Effective Comparison of Letrozole and Tamoxifen in the Neoadjuvant Endocrine Therapy of Postmenopausal Breast Cancer

Progresses in adjuvant endocrine treatment of pre -menopausal patients with breast cancer

[Neoadjuvant endocrine therapy for locally advanced breast cancer]

Optimal sequence of adjuvant endocrine and radiation therapy in early-stage breast cancer - A systematic review

Efficacy and Safety of Endocrine Therapy for Breast-Cancer Prevention in High-Risk Premenopausal or Postmenopausal Women: a Bayesian Network Meta-Analysis of Nine Randomized Controlled Trials